EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Weal and woe of interleukin-18 in the T cell therapy of cancer

Christoph Kessel, Claudia Rossig, Hinrich Abken

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-010545 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Christoph Kessel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Translational Inflammation Research, Department of Pediatric Rheumatology & Immunology, University of Münster Faculty of Medicine, Munster, Germany. Hauptthemen laut MEDLINE: Interleukin-18, Neoplasms, Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, Deutsche Krebshilfe, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cell therapy of solid cancer remains below expectations; adding cytokine help through IL-18 has shown remarkable efficacy in first clinical trials. As IL-18 is also a powerful driver of hyperinflammatory conditions, we discuss to what extent unleashing IL-18 is a double-edged sword in CAR T cell therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-18NeoplasmsImmunotherapy, AdoptiveT-LymphocytesHumansReceptors, Chimeric Antigen

Stichwörter der Autor:innen

Adoptive cell therapy - ACTChimeric antigen receptor - CARCytokineImmune related adverse event - irAET cell

Substanzen

Interleukin-18Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Translational Inflammation Research, Department of Pediatric Rheumatology & Immunology, University of Münster Faculty of Medicine, Munster, Germany.
  • Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Munster, Germany.
  • Prinses Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Division Genetic Immunotherapy, Leibniz Institute for Immunotherapy, Regensburg, Germany Hinrich.Abken@klinik.uni-regensburg.de.
  • Universitätsklinikum Regensburg, Regensburg, Germany.

Förderung

  • Bundesministerium für Bildung und Forschung
  • Deutsche Krebshilfe
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Kessel, C., Rossig, C., & Abken, H. (2025). Weal and woe of interleukin-18 in the T cell therapy of cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010545

Vancouver

Kessel C, Rossig C, Abken H. Weal and woe of interleukin-18 in the T cell therapy of cancer. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010545

BibTeX
@article{Kessel2025,
  author = {Kessel, Christoph and Rossig, Claudia and Abken, Hinrich},
  title = {Weal and woe of interleukin-18 in the T cell therapy of cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-010545}
}
Kostenlos starten →